Skip to main content

Gyroscope Therapeutics Holdings Ltimited (VISN)

Gyroscope Therapeutics Holdings Ltimited was planning to go public, but the IPO has been postponed.
Stock Price: $20.00 - $22.00
Current IPO price range

Company Description

Gyroscope Therapeutics is a global clinical-stage gene therapy company developing gene therapy beyond rare diseases.

Our mission is to preserve sight and fight the devastating impact of blindness. Our science is grounded in the genetic understanding of patients with serious eye diseases to make medicines designed to have a meaningful impact.

Our initial focus is age-related macular degeneration, or AMD, one of the leading causes of irreversible blindness, affecting more than 196 million people worldwide.

We are developing a differentiated pipeline of recombinant adeno-associated virus, or rAAV, gene therapy candidates targeting genetic variants in the complement pathway that we believe to be key drivers of AMD.

Our investigational gene therapies are designed as one-time treatments. Our lead investigational gene therapy, GT005, is advancing in an ongoing Phase I/II clinical trial and is being evaluated in Phase II clinical trials in two different genetically defined patient populations with geographic atrophy, or GA, an advanced form of dry AMD.

We have received Fast Track designation from the U.S. Food and Drug Administration, or the FDA, for GT005 for the treatment of GA secondary to AMD.

Gyroscope Therapeutics Holdings Ltimited
CountryUnited Kingdom
Founded2016
IndustryBiological Products
SectorBiotechnology
Employees167
CEOKhurem Farooq

Contact Details

Address:
Stevenage Bioscience Catalyst, Gunnels Wood Road
Stevenage, Hertfordshire SG1 2FX
United Kingdom
Phone+ 44 (0)1438 906770
Websitegyroscopetx.com

Stock Details

Ticker SymbolVISN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1837620

Key Executives

NamePosition
Khurem FarooqChief Executive Officer and Director
Jane Hughes, Ph.D.Chief Scientific Officer
Edward Lang Jr.Chief Business Officer
Ian Pitfield, Ph.D.Senior Vice President, Technical Operations
Jessica StittChief Financial Officer
Nadia Waheed, M.D.Chief Medical Officer
Chris Hollowood, Ph.D.Chairman of the Board of Directors
Sean Bohen, M.D., Ph.D.Non-Executive Director

Latest SEC Filings

DateTypeTitle
Jun 10, 2021RWRegistration Withdrawal Request
May 6, 2021CERTCertification by an exchange approving securities for listing
May 4, 20218-A12BRegistration of securities [Section 12(b)]
May 3, 2021F-1/ARegistration statement for certain foreign private issuers
Apr 27, 2021F-1/ARegistration statement for certain foreign private issuers
Apr 16, 2021F-1Registration statement for certain foreign private issuers
Apr 1, 2021DRS/ADraft Registration Statement
Feb 19, 2021DRS/ADraft Registration Statement
Jan 11, 2021DRSDraft Registration Statement
View All SEC Filings